The standard treatment for
autoimmune pancreatitis (AIP) is
steroid therapy, although some patients improve spontaneously. Indications for
steroid therapy in AIP patients are symptoms such as
obstructive jaundice,
abdominal pain,
back pain, and the presence of symptomatic extrapancreatic lesions. Prior to
steroid therapy,
obstructive jaundice should be managed by biliary drainage, and
blood glucose levels should be controlled in patients with
diabetes mellitus. The recommended initial oral
prednisolone dose for
induction of remission is 0.6 mg/kg/day, which is administered for 2-4 weeks. The dose is then tapered by 5 mg every 1-2 weeks, based on changes in clinical manifestations, biochemical blood tests (such as liver
enzymes and
IgG or
IgG4 levels), and repeated imaging findings (US, CT, MRCP, ERCP, etc.). The dose is tapered to a maintenance dose (2.5-5 mg/day) over a period of 2-3 months. Cessation of
steroid therapy should be based on the disease activity in each case. Termination of maintenance
therapy should be planned within 3 years in cases with radiological and serological improvement. Re-administration or dose-up of
steroid is effective for treating AIP relapse. Application of
immunomodulatory drugs is considered for AIP patients who prove resistant to
steroid therapy. The prognosis of AIP appears to be good over the short-term with
steroid therapy. The long-term outcome is less clear, as there are many unknown factors, such as relapse, pancreatic exocrine or endocrine dysfunction, and associated
malignancy.